# Catumaxomab

Catumaxomab (Korjuny, Atnahs Pharma Netherlands B.V.) has 1 EU-approved indication in 1 tumour type. It needs a biomarker result: EpCAM (1).

## Approved indications

### Solid tumours, tumour-agnostic

| Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|
| EpCAM-positive | Monotherapy | 2nd line | Malignant ascites; not eligible for further systemic anticancer therapy Ambiguous in the label (tumour site, line of therapy): check the SmPC. |

## Products

### Korjuny

- Company: Atnahs Pharma Netherlands B.V.
- Target: EpCAM × CD3 bispecific trifunctional antibody
- Class: Other monoclonal antibodies and antibody drug conjugates
- ATC: L01FX03
- EU approval: 10 Feb 2025
- Label revised: 6 May 2026
- SmPC (EN): https://www.ema.europa.eu/en/documents/product-information/korjuny-epar-product-information_en.pdf
- Fachinformation (DE): https://www.ema.europa.eu/de/documents/product-information/korjuny-epar-product-information_de.pdf
- EPAR: https://www.ema.europa.eu/en/medicines/human/EPAR/korjuny

Mechanism (SmPC section 5.1): Binds EpCAM on tumour cells and CD3 on T cells, and engages accessory immune cells via its Fc region, bringing them together to kill tumour cells (T-cell killing, ADCC, CDC, phagocytosis).

## Label wording

- **Catumaxomab** (Korjuny), Solid tumours, tumour-agnostic, 2nd line: “Korjuny is indicated for the intraperitoneal treatment of malignant ascites in adults with epithelial cellular adhesion molecule (EpCAM)-positive carcinomas, who are not eligible for further systemic anticancer therapy.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/korjuny-epar-product-information_en.pdf)

Source: section 4.1 of each summary of product characteristics (SmPC), EMA data as of 5 Nov 2026. AI models structured these entries and no person has checked them yet. oncolabels is a non-commercial reference for education and research and gives no medical advice; the current SmPC takes precedence.

Data under CC BY 4.0: credit oncolabels and the European Medicines Agency. Page: https://oncolabels.com/drugs/catumaxomab